All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
N-Hexanoic-Tyr-Ile-(6) Aminohexanoic Amide
For educational and research purposes only. Not medical advice.
Dihexa shows extraordinary potency for synaptogenesis in animal models but has almost no human data. The HGF activation mechanism raises theoretical cancer concerns. High-risk, high-potential compound in early research stage. Use with extreme caution.
Best Time
Morning
Method
oral
Frequency
Daily
Half-life
~12 hours
Cycle Length
4-8 weeks
Storage
Room temperature, dry place.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Neuroscience and biobehavioral reviews 92 :209-225 · 2018-09-01
The Journal of pharmacology and experimental therapeutics 344 (1) :141-54 · 2013-01-01
Biomicrofluidics 8 (5) :52005 · 2014-09-01
Photochemistry and photobiology 81 (3) :569-72 · 2005-01-01
The American journal of physiology 263 (2 Pt 1) :L201-9 · 1992-08-01
Mechanism of Action
Angiotensin IV analog that activates hepatocyte growth factor (HGF) signaling. Promotes dendritic spine formation and synaptic connectivity. Reported to be 10 million times more potent than BDNF for synaptogenesis.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.